Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

FDA Expands Approval of Lorlatinib for Frontline ALK+ NSCLC

March 4th 2021

The FDA has expanded the indication for lorlatinib to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

The Many Shades of KRAS: Investigators Seek to Exploit Heterogeneity in Mutations

March 3rd 2021

KRAS has topped the most wanted list of therapeutic targets in oncology for decades, but it has resolutely resisted all efforts, garnering it a reputation as undruggable.

FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC

March 1st 2021

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

FDA Approval Sought for Ivosidenib in Previously Treated IDH1-Mutant Cholangiocarcinoma

March 1st 2021

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Biomarker-Guided Therapies, Novel Combos Take Center Stage in Urothelial Carcinoma

February 23rd 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Next-Generation Sequencing Reveals Potentially Actionable Mutations in Sarcoma

February 18th 2021

February 18, 2021 — The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.

FDA Grants Priority Review to Sotorasib for KRAS G12C–Mutated Advanced or Metastatic NSCLC

February 17th 2021

February 16, 2021 - The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome

February 16th 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer

February 15th 2021

Dr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.

Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors

February 11th 2021

Dr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.

Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC

February 8th 2021

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

February 5th 2021

Lori J. Wirth, MD, , discusses the potential impact of pralsetinib on the thyroid cancer treatment landscape.

Gilteritinib Receives Conditional Approval in China for FLT3+ AML

February 4th 2021

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

Seribantumab May Hold Pan-Tumor Potential in Cancers With NRG1 Fusions

February 3rd 2021

Investigators are seeking to determine whether seribantumab, a novel monoclonal antibody, can effectively treat patients with solid tumors that harbor rare NRG1 fusions.

Dr. Gralow on the Integration on Precision Medicine Into Oncology

February 2nd 2021

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

February 2nd 2021

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.